Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Treasury Shares (2019 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Treasury Shares for 7 consecutive years, with $99232.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares fell 98.78% year-over-year to $99232.0, compared with a TTM value of $99232.0 through Sep 2025, down 98.78%, and an annual FY2024 reading of $198995.0, down 93.62% over the prior year.
  • Treasury Shares was $99232.0 for Q3 2025 at X4 Pharmaceuticals, down from $333264.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $8.4 million in Q1 2024 and bottomed at $99232.0 in Q3 2025.
  • Average Treasury Shares over 5 years is $3.0 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Treasury Shares skyrocketed 298.83% in 2023, then tumbled 98.78% in 2025.
  • Year by year, Treasury Shares stood at $925101.0 in 2021, then soared by 81.66% to $1.7 million in 2022, then surged by 85.58% to $3.1 million in 2023, then tumbled by 93.62% to $198995.0 in 2024, then tumbled by 50.13% to $99232.0 in 2025.
  • Business Quant data shows Treasury Shares for XFOR at $99232.0 in Q3 2025, $333264.0 in Q2 2025, and $327972.0 in Q1 2025.